The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | BTK and BCL2 inhibitor resistance in CLL: session highlights
Lukas Frenzel, MD, University of Cologne, Cologne, Germany, gives an overview of a session that was held at ESH CLL 2022, which focused on Bruton’s tyrosine kinase (BTK) and BCL-2 inhibitor resistance in chronic lymphocytic leukemia (CLL). Dr Frenzel first highlights how this session touched on both covalent and non-covalent BTK inhibitor resistance, which provides important information for better understanding CLL treatment. Following this, Dr Frenzel draws focus on mechanisms behind venetoclax resistance, including the role of mutations in BCL-2 and cell cycle regulator genes. To conclude, Dr Frenzel highlights a presentation which focused on the role of TP53 mutation and other targeted mutations in CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Abbvie Advisory board
